Life Sciences M&A Activity Signals Strategic Shift Toward Larger, High-Stakes Deals
Risk & Insurance - Jan 29, 2026
Despite declining transaction volume in 2024, life sciences companies are pursuing bigger acquisitions to secure drug portfolios, integrate AI capabilities, and navigate the looming patent cliff. The post Life Sciences M&A Activity Signals Strategic Shift Toward Larger, High-Stakes Deals appea...
Recommended Articles
Posted: Jan 29, 2026
As AI reshapes the competitive landscape, technology companies are pursuing bigger acquisitions desp...
Posted: Jan 29, 2026
US and Canadian professionals see steady increases in compensation, with seniority and supervisory r...
Posted: Jan 28, 2026
Out-of-network pharmacy use in workers’ compensation drives higher costs, safety risks, and regulato...